European CHMP recommends approval of ponesimod (Ponvory) for treatment of adults with relapsing forms of multiple sclerosis

Ponesimod, an oral selective sphingosine-1-phosphate receptor 1 modulator, has been demonstrated to prevent relapses and occurrence of new focal inflammatory lesions in the CNS.

Source:

European Medicines Agency